Neuronetics (STIM) Q2 2026 earnings review
Profitability Breakthrough Masks Legacy Revenue Weakness
Neuronetics hit a major operational milestone in Q2 2026 by delivering positive Adjusted EBITDA ($0.3M) and significantly reducing its cash burn to just $1.4M. The margin expansion story is highly compelling, driven by a 12% YoY reduction in operating expenses and a 450-basis-point jump in gross margins to 51.1%. However, the top-line narrative is deeply bifurcated. While the Greenbrook clinic network continues to act as a robust growth engine (+16.8% YoY), the legacy NeuroStar equipment and session business remains stuck in contraction (-2.7% YoY). Management's slight reduction of the top-end of FY26 revenue guidance suggests the NeuroStar turnaround will take time, but raised profitability guidance proves the new leadership team is successfully executing on its mandate to protect the balance sheet.
🐂 Bull Case
Operating expenses fell 12% to $22.7M, and the company raised its full-year gross margin guidance to 48-50%. The disciplined path to sustainable positive cash flow is now visible.
The clinic segment grew 16.8% to $26.9M. The ongoing rollout and optimization of SPRAVATO inside these clinics is effectively diversifying revenue away from purely hardware and TMS sessions.
🐻 Bear Case
Legacy NeuroStar revenue fell 2.7% to $14.7M. The core capital equipment and partnership session volume is struggling to gain traction despite broader market awareness.
Management lowered the top-end of FY26 revenue guidance by $2M to $164M, implying that macro or competitive headwinds are capping near-term growth ceilings.
⚖️ Verdict: ⚪
Neutral. The aggressive pivot toward profitability is excellent for survival and reduces dilution risk, but a med-tech company cannot shrink its core product line indefinitely. Re-accelerating NeuroStar capital placements is required for a bullish upgrade.
Key Themes
Aggressive Operating Leverage Realized
The most important takeaway from this quarter is the reversing trend in profitability. The company slashed Operating Expenses by $3.1M (-12% YoY) while growing overall revenue 9.1%. Consequently, Loss from Operations improved dramatically from $8.1M to $1.5M YoY. Management subsequently lowered FY26 OpEx guidance from $100-$105M down to $95-$100M, proving they are structurally lowering the breakeven point.
Legacy NeuroStar Segment Lags
While Greenbrook flourishes, the foundational NeuroStar segment (equipment and treatment sessions) declined 2.7% YoY to $14.67M. For a company attempting to expand its installed base to 800+ sites, the inability to drive organic hardware and session growth is a significant red flag that contradicts the overall growth narrative.
Go-to-Market Strategy Overhaul
To address the NeuroStar weakness, the new leadership team is pivoting from a single 'high-touch partnership' model to a tiered three-pronged approach: Capital (Purchase outright), Lease (Finance over time), and Sessions (traditional partnership). This flexibility is designed to lower the barrier to entry for smaller or budget-constrained clinics, though it remains to be seen if it will cannibalize higher-margin session revenues.
Greenbrook and Spravato Synergies
Greenbrook clinic revenue reached $26.9M, up 16.8% YoY. The strategy of leveraging a fixed national footprint to cross-sell SPRAVATO alongside traditional TMS is working, evidenced by improved revenue cycle management and gross margins expanding to 51.1% from 46.6% a year ago.
Leadership Restructuring
Following the recent CEO transition to Dan Reuvers, the company has completely rebuilt its C-suite. Q2 saw the appointment of Nir Naor as CFO, the promotion of Cory Anderson to GM of Greenbrook, and the hiring of Rob Greene as SVP of Sales. This team's immediate focus on structural cash flow indicates a sharp departure from the previous 'growth-at-all-costs' regime.
Other KPIs
Accelerating. An impressive 450 basis point YoY improvement from 46.6% in 25Q2. Management cited a shift in go-to-market strategy and vastly improved revenue cycle management inside the Greenbrook clinics as the primary drivers.
Reversing trend. Cash burn was slashed by $2.3 million compared to the $3.8 million used in Q2 2025. With $25 million in total cash on the balance sheet, the company's runway is now looking significantly more secure than it did 12 months ago.
Guidance
Stable but slightly decelerating at the top end. The previous guidance was $160-$166 million. The midpoint of $162 million implies roughly 8.5% YoY growth compared to FY25's $149 million.
Accelerating. Raised from prior guidance of 47% - 49%, reflecting the strong 51.1% print in Q2 and structural improvements in clinic billing collections.
Decelerating. This is a crucial $5 million reduction from the previous $100-$105 million guidance range. Excluding roughly $4 million in stock-based compensation, cash OpEx is targeted at just $91-$96 million, showcasing strict cost discipline.
Accelerating compared to previous guidance which projected negative $13 million to negative $17 million for operations *alone*. The new combined metric shows a significantly shallower projected cash burn.
Key Questions
NeuroStar Core Contraction
With legacy NeuroStar revenue declining 2.7% year-over-year, what specific timeline does management have for returning the core capital and session business to positive growth?
New Go-To-Market Economics
How do the margin profiles of the newly introduced 'Capital' and 'Lease' models compare to the traditional 'Partnership/Session' model, and are you seeing early signs of cannibalization?
SPRAVATO Concentration Risk
As SPRAVATO becomes a larger driver of Greenbrook's double-digit growth, how is the company hedging against potential future reimbursement rate compressions from commercial payers?
Path to Free Cash Flow
Given Q2's cash usage was reduced to just $1.4 million, is it reasonable to expect the company will achieve sustained, positive free cash flow before the end of FY26?